Oral Glucagon-Like Peptide (GLP)-1 Weight Loss Drug Market Report 2026

Oral Glucagon-Like Peptide (GLP)-1 Weight Loss Drug Market Overview

• Oral Glucagon-Like Peptide (GLP)-1 Weight Loss Drug market size has reached to $18.27 billion in 2025 • Expected to grow to $84.18 billion in 2030 at a compound annual growth rate (CAGR) of 35.8% • Growth Driver: The Increasing Prevalence Of Obesity Driving The Growth Of The Market Due To Unhealthy Dietary Habits • Market Trend: Advancement In Flexible-Dosing Oral Formulations Enhancing Chronic Weight Management Outcomes • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Oral Glucagon-Like Peptide (GLP)-1 Weight Loss Drug Market?

Oral glucagon-like peptide (GLP)-1 weight loss drugs refer to orally administered medications that mimic or enhance the action of the GLP-1 hormone to regulate appetite, slow gastric emptying, and improve blood sugar control, thereby supporting weight reduction. These drugs are primarily used for obesity and type 2 diabetes management and offer a non-injectable alternative to traditional GLP-1 therapies. The main drug types of oral glucagon-like peptide (GLP)-1 weight loss drug include orforglipron, oral semaglutide, and next generation oral glucagon like peptide one. Orforglipron refers to an oral small-molecule GLP-1 receptor agonist designed to support weight loss and metabolic control without injectable administration. These drugs are used across patient types including non diabetic patients, diabetic patients, adult population, adolescent population, and elderly population and are indicated for obesity management, overweight with comorbidities, type two diabetes with obesity, cardiovascular risk reduction, and weight maintenance. They are distributed through retail pharmacy, direct to consumer, and hospital pharmacy channels and are utilized by end users including hospitals, obesity clinics, homecare or self administered users, and specialty metabolic centers.

What Is The Oral Glucagon-Like Peptide (GLP)-1 Weight Loss Drug Market Growth Forecast?

The oral glucagon-like peptide (GLP)-1 weight loss drug market size is expected to see exponential growth in the next few years. It will grow to $84.18 billion in 2030 at a compound annual growth rate (CAGR) of 35.8%. The growth in the forecast period can be attributed to growing demand for non invasive weight loss solutions, expansion of next generation oral peptide alternatives, increasing adoption of personalized obesity management therapies, rising reimbursement support for metabolic drugs, continuous pipeline advancements in small molecule glp-1 therapies. Major trends in the forecast period include oral glp-1 small molecule innovation for weight management, expansion of non injectable obesity treatment adoption, increasing demand for once daily metabolic control therapies, rising focus on long term appetite regulation drugs, growing shift toward combination therapy in obesity and type 2 diabetes management.

Global Oral Glucagon-Like Peptide (GLP)-1 Weight Loss Drug Market Segmentation

1) By Drug Type: Orforglipron, Oral Semaglutide, Next Generation Oral Glucagon Like Peptide One 2) By Patient Type: Non Diabetic Patients, Diabetic Patients, Adult Population, Adolescent Population, Elderly Population 3) By Indication: Obesity Management, Overweight With Comorbidities, Type Two Diabetes With Obesity, Cardiovascular Risk Reduction, Weight Maintenance 4) By Distribution Channel: Retail Pharmacy, Direct To Consumer, Hospital Pharmacy 5) By End User: Hospitals, Obesity Clinics, Homecare Or Self Administered Users, Specialty Metabolic Centers Subsegments: 1) By Orforglipron: Once Daily Oral Formulations, Small Molecule Glucagon Like Peptide One Therapies, Obesity Management Therapies, Type Two Diabetes Management Therapies, Combination Metabolic Therapies 2) By Oral Semaglutide: Tablet Based Peptide Therapies, Once Daily Oral Therapies, Weight Management Therapies, Cardiometabolic Risk Reduction Therapies, Long Term Chronic Weight Control Therapies 3) By Next Generation Oral Glucagon Like Peptide One Therapies: Dual Agonist Oral Therapies, Triple Agonist Oral Therapies, Non Peptide Oral Therapies, Extended Release Oral Therapies, Precision Metabolic Therapies

What Is The Driver Of The Oral Glucagon-Like Peptide (GLP)-1 Weight Loss Drug Market?

The increasing prevalence of obesity is expected to propel the growth of the oral glucagon-like peptide (GLP)-1 weight loss drug market going forward. Obesity refers to a medical condition characterized by excessive accumulation of body fat that may negatively affect health and increase the risk of diseases such as diabetes, heart disease, and hypertension. The increasing prevalence of obesity is primarily due to unhealthy dietary habits, including excessive consumption of high-calorie, processed, and sugary foods combined with low physical activity levels. Oral glucagon-like peptide (GLP)-1, a weight-loss drug, helps manage obesity by regulating appetite, reducing calorie intake, and improving metabolic control, thereby supporting effective and sustained weight reduction. For instance, in May 2025, according to the Office for Health Improvement and Disparities, a UK-based government body, from 2023 to 2024, an estimated 64.5% of adults aged 18 and over in England were overweight or living with obesity, up from 64.0% in 2022 to 2023. Therefore, the increasing prevalence of obesity is driving the growth of the oral glucagon-like peptide (GLP)-1 weight loss drug industry.

Key Players In The Global Oral Glucagon-Like Peptide (GLP)-1 Weight Loss Drug Market

Major companies operating in the oral glucagon-like peptide (glp)-1 weight loss drug market are Novo Nordisk A/S, Eli Lilly and Company, AstraZeneca PLC, Innovent Biologics Inc., Hansoh Pharmaceutical Group, Hanmi Pharmaceutical Co Ltd., Amgen, Jiangsu Hengrui Pharmaceuticals Co Ltd., Viking Therapeutics Inc., Structure Therapeutics Inc., Biomea Fusion Inc., Oramed Pharmaceuticals Inc., Sciwind Biosciences Co. Ltd., Septerna Inc., D And D Pharmatech Inc., Kailera Therapeutics Inc., Eccogene Inc.

Global Oral Glucagon-Like Peptide (GLP)-1 Weight Loss Drug Market Trends and Insights

Major companies operating in the oral glucagon-like peptide (GLP)-1 weight loss drug market are focusing on developing non-peptide small molecule solutions, such as flexible-dosing oral formulations, to enhance patient adherence, expand accessibility beyond injectables, and deliver superior weight loss outcomes. Flexible-dosing oral formulations refer to medicines designed to be taken conveniently at different times or conditions without strict requirements related to meals, water intake, or precise scheduling. For instance, in April 2026, Eli Lilly and Company, a US-based pharmaceutical company, received U.S. Food and Drug Administration (FDA) approval for Foundayo (orforglipron), its once-daily oral GLP-1 receptor agonist, the only non-peptide pill approved for adults with obesity or overweight with weight-related conditions. Designed to support chronic weight management alongside diet and exercise, the therapy achieved an average 27 pounds (12.4%) weight loss on the highest dose in the Phase 3 ATTAIN-1 trial versus 2.2 pounds on placebo, with reductions in cardiovascular risk markers such as waist circumference and triglycerides.

What Are Latest Mergers And Acquisitions In The Oral Glucagon-Like Peptide (GLP)-1 Weight Loss Drug Market?

In November 2025, Pfizer Inc., a US-based pharmaceutical company, acquired Metsera for $10 billion. With this acquisition, Pfizer aims to strengthen its position in the rapidly growing obesity and cardiometabolic treatment market by expanding its pipeline with next-generation oral and injectable GLP-1 and amylin-based therapies. Metsera Inc. is a US-based company that is developing an oral GLP-1 receptor agonist (RA) for weight loss.

Regional Outlook

North America was the largest region in the oral glp-1 weight loss drug market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Oral Glucagon-Like Peptide (GLP)-1 Weight Loss Drug Market?

The oral glucagon-like peptide (GLP)-1 weight loss drug market consists of sales of oral glucagon-like peptide-1 receptor agonist medications, anti-obesity prescription drugs, and oral metabolic disorder treatment products. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Oral Glucagon-Like Peptide (GLP)-1 Weight Loss Drug Market Report 2026?

The oral glucagon-like peptide (GLP)-1 weight loss drug market research report is one of a series of new reports from The Business Research Company that provides oral glucagon-like peptide (GLP)-1 weight loss drug market statistics, including oral glucagon-like peptide (GLP)-1 weight loss drug industry global market size, regional shares, competitors with a oral glucagon-like peptide (GLP)-1 weight loss drug market share, detailed oral glucagon-like peptide (GLP)-1 weight loss drug market segments, market trends and opportunities, and any further data you may need to thrive in the oral glucagon-like peptide (GLP)-1 weight loss drug industry. This oral glucagon-like peptide (GLP)-1 weight loss drug market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.